Neuropathy and levodopa in Parkinson's disease: Evidence from a multicenter study

• Published in: Movement disorders Vol. 28; no. 10; pp. 1391 - 1397
• Main Authors: Ceravolo, Roberto, Cossu, Giovanni, Bandettini di Poggio, Monica, Santoro, Lucio, Barone, Paolo, Zibetti, Maurizio, Frosini, Daniela, Nicoletti, Valentina, Manganelli, Fiore, Iodice, Rosa, Picillo, Marina, Merola, Aristide, Lopiano, Leonardo, Paribello, Alessandra, Manca, Davide, Melis, Maurizio, Marchese, Roberta, Borelli, Paolo, Mereu, Alessandra, Contu, Paolo, Abbruzzese, Giovanni, Bonuccelli, Ubaldo
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.09.2013; Wiley Subscription Services, Inc
• Subjects: Aged; Antiparkinson Agents - adverse effects; Antiparkinson Agents - therapeutic use; Confidence intervals; Female; Homocysteine; Homocysteine - blood; Humans; Hyperhomocysteinemia - chemically induced; Levodopa - adverse effects; Levodopa - therapeutic use; Logistic Models; Male; Middle Aged; Movement disorders; Neural Conduction - drug effects; Parkinson Disease - complications; Parkinson Disease - drug therapy; Parkinson Disease - epidemiology; Parkinson's disease; Peripheral Nervous System Diseases - chemically induced; Peripheral Nervous System Diseases - epidemiology; Peripheral Nervous System Diseases - physiopathology; peripheral neuropathy; Prevalence; Risk; Vitamin B 12 - blood; peripheral neuropathy; Parkinson's disease
• ISSN: 0885-3185; 1531-8257; 1531-8257
• DOI: 10.1002/mds.25585

ABSTRACT The objectives of this study were to evaluate the risk of neuropathy in patients with Parkinson's disease (PD) and to evaluate the role of levodopa exposure as a potential risk factor. A multicenter study of 330 patients with PD and 137 healthy controls with a comparable age distribution was performed. With respect to levodopa exposure, 144 patients had long exposure (≥3 years) to levodopa (LELD), 103 patients had short exposure (<3 years) to levodopa (SELD), and 83 patients had no exposure to levodopa (NOLD). Nerve function was evaluated using the reduced total neuropathy score. Right sural sensory antidromic and peroneal motor nerve conduction studies were performed by neurophysiologists who were blinded to the existence of neuropathy clinical features or PD treatment. Overall, 19.40% of patients in the LELD group, 6.80% in the SELD group, 4.82% in the NOLD group, and 8.76% in the control group were diagnosed with neuropathy (axonal, predominantly sensory). Multivariate logistic analysis indicated that the risk of neuropathy was not influenced by disease duration, severity, or sex. The risk of neuropathy increased by approximately 8% for each year of age (P < 0.001; odds ratio [OR], 1.08; 95% confidence interval [CI], 1.037‐1.128). The risk of neuropathy was 2.38 higher in the LELD group than in the control group (P = 0.022; OR, 2.38; 95% CI, 1.130‐5.014). In a comparison between patients with and without neuropathy (Student's t test), the levodopa dose was higher (P < 0.0001), serum vitamin B12 levels were lower (P = 0.0102), and homocysteine levels were higher (P < 0.001) in the patients with neuropathy. Our results demonstrate that the duration of exposure to levodopa, along with age, is the main risk factor for the development of neuropathy. Screening for homocysteine and vitamin B12 levels and clinical‐neurophysiological monitoring for neuropathy may be advisable in patients with PD who are receiving treatment with levodopa. © 2013 International Parkinson and Movement Disorder Society